VSY Biotechnology

VSY Biotechnology is a Germany-based healthcare and medical technology company focused primarily on ophthalmology and orthopedics. The company develops, manufactures, and commercializes intraocular lenses, ophthalmic viscoelastic devices, cartridge and injector systems, and hyaluronic-acid-based orthopedic products, with additional activity in medical aesthetics. Its ophthalmology portfolio includes the Enova and Acriva IOL families, including premium presbyopia-correcting and toric lenses, supported by proprietary technologies such as Sinusoidal Vision Technology and the Rotaryjet preloaded injector system. VSY also markets orthobiologic viscosupplement products such as Re-Cross for pain management and osteoarthritic conditions. The company operates internationally, serves more than 90 countries, and has been part of Evmann Investments Holding since 2021.